Inside the research
United Therapeutics Corporation
UTHR Research profile · latest available data
Price overview
$475.45
▲ +3.24 (+0.7%)
| 52w hi | $596.76 |
|---|---|
| 52w lo | $415.34 |
| Vol | 472.40K |
| As of | 25 Sep 2026 |
The Verdict
Our score -0.17
| Short | -0.44 |
|---|---|
| Medium | -0.08 |
| Long | +0.19 |
computed 2026-09-27
Key fundamentals
United Therapeutics Corporation
Healthcare · Drug Manufacturers - Specialty & Generic
| Market cap | $20.39B |
|---|---|
| Enterprise value | $17.73B |
| Trailing P/E | 17.66x |
| Forward P/E | 15.83x |
| EV / EBITDA | 11.85x |
| P / S (ttm) | 6.46x |
| Profit margin | 41.6% |
| Return on equity | 19.3% |
| Revenue growth | -1.9% |
| Earnings growth | +13.4% |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.26 | |
| Sector | +0.08 | |
| Technical | -0.30 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
Risk Metrics
| Beta vs SPX | 0.42 |
|---|---|
| Corr SPX | 0.16 |
| Annual vol | 41.0% |
| Annual ret | +22.8% |
| Sharpe | 0.56 |
| Max DD | -33.0% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $662.54 |
|---|---|
| High / Low | $750.00 / $516.00 |
| Median | $675.00 |
| Analysts | 13 |
| Strong Buy | 2 | |
|---|---|---|
| Buy | 9 | |
| Hold | 3 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-05-07 | Wells Fargo | → Overweight |
| 2026-05-07 | RBC Capital | → Outperform |
| 2026-04-10 | Morgan Stanley | → Equal-Weight |
| 2026-03-31 | Wells Fargo | → Equal-Weight |
| 2026-03-31 | HC Wainwright & Co. | → Buy |
| 2026-03-31 | B of A Securities | → Neutral |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-05 | Earnings Release, Exhibits | read |
| 2026-07-23 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-06-29 | Officer / Director Change, Shareholder Vote… | read |
| 2026-05-06 | Earnings Release, Exhibits | read |
| 2026-03-30 | Other Material Event, Exhibits | read |
| 2026-03-09 | Material Agreement, Reg FD Disclosure… | read |
| 2026-03-02 | Reg FD Disclosure, Exhibits | read |
| 2026-02-25 | Earnings Release, Exhibits | read |
| 2026-01-22 | Officer / Director Change, Bylaws Amendment… | read |
| 2025-10-29 | Earnings Release, Exhibits | read |
| 2025-09-02 | Other Material Event, Exhibits | read |
| 2025-08-01 | Material Agreement, Reg FD Disclosure… | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-13 | ROTHBLATT MARTINE A | Director, Officer, Chairp | Option exercise | 9.50K | $1.29M |
| 2026-08-13 | ROTHBLATT MARTINE A | Director, Officer, Chairp | Sell | 1.25K | $626.60K |
| 2026-08-13 | ROTHBLATT MARTINE A | Director, Officer, Chairp | Sell | 1.33K | $665.24K |
| 2026-08-13 | ROTHBLATT MARTINE A | Director, Officer, Chairp | Sell | 1.52K | $762.35K |
| 2026-08-13 | ROTHBLATT MARTINE A | Director, Officer, Chairp | Sell | 440 | $221.29K |
| 2026-08-13 | ROTHBLATT MARTINE A | Director, Officer, Chairp | Sell | 160 | $80.61K |
| 2026-08-13 | ROTHBLATT MARTINE A | Director, Officer, Chairp | Sell | 961 | $485.48K |
| 2026-08-13 | ROTHBLATT MARTINE A | Director, Officer, Chairp | Sell | 1.68K | $849.84K |
| 2026-08-13 | ROTHBLATT MARTINE A | Director, Officer, Chairp | Sell | 920 | $466.57K |
| 2026-08-13 | ROTHBLATT MARTINE A | Director, Officer, Chairp | Sell | 640 | $325.61K |
Flow & Concentration
| Insider 180d net | -$48.07M |
|---|---|
| Insider buys / sells | 0 / 117 |
| Insider bias | Sellers |
| 13F holders | 0 |
| Top-5 share | 0.0% |
| HHI | 0 (—) |
SEC Filings
The Long Run
FY 2010–2025 · 16 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $2.88B | +11.0% | |
| Gross profit | $2.80B | +27.5% | |
| Operating income | $1.49B | +33.6% | |
| Net income | $1.33B | +67.5% | |
| Cash from ops | $1.56B | +24.9% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $474.04 | $479.97 | $470.40 | $475.45 | 472.40K |
| Sep 24 | $472.72 | $481.32 | $468.97 | $472.21 | 585.50K |
| Sep 23 | $498.82 | $500.05 | $487.73 | $489.42 | 433.40K |
| Sep 22 | $493.98 | $499.58 | $488.08 | $497.59 | 586.40K |
| Sep 21 | $497.70 | $497.70 | $491.26 | $493.10 | 1.19M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →